Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Ning Chow und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, Hepatitis B. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: General Research Fund, Research Grants Council, The Government of the Hong Kong Special Administrative Region.
Abstract (Originalsprache)
Background
This study investigated the effect of nucleos(t)ide analogue (NUC) treatment on hepatitis B virus (HBV) DNA integration and hepatocyte clonal expansion, both of which are implicated in hepatocellular carcinoma (HCC) in chronic hepatitis B.
Methods
Twenty-eight patients receiving NUCs (11 lamivudine, 7 telbivudine, 10 entecavir) were included. All had liver biopsies at baseline and year 1, and 7 had a third biopsy at year 10. HBV DNA integration and hepatocyte clone size were assessed by inverse polymerase chain reaction.
Results
All patients had detectable HBV integration at baseline, with a median integration frequency of 1.01 × 109 per liver and hepatocyte clone size of 2.41 × 105. Neither integration frequency nor hepatocyte clone size correlated with age and HBV virologic parameters. After 1 year of treatment, HBV integration was still detectable in all patients, with a median of 5.74 × 108 integration per liver (0.22 log reduction; P = .008) and hepatocyte clone size of 1.22 × 105 (0.40 log reduction; P = .002). HBV integration remained detectable at year 10 of treatment, with a median integration frequency of 4.84 × 107 integration per liver (0.93 log reduction from baseline) and hepatocyte clone size of 2.55 × 104 (1.02 log reduction from baseline). From baseline through year 1 to year 10, there was a decreasing trend in both integration frequency and hepatocyte clone size (P = .066 and.018, respectively).
Conclusions
NUCs reduced both HBV DNA integration and hepatocyte clonal expansion, suggesting another alternative pathway besides direct viral suppression to reduce HCC risk. Our findings supported the notion for a long-term NUC treatment to prevent HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
- State Key Laboratory of Liver Research, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
- Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
ORCID-Profile: Danny Wong
Förderung
- General Research Fund
- Research Grants Council
- The Government of the Hong Kong Special Administrative Region
Zitieren
APA
Chow, N., Wong, D., Lai, C. L., Mak, L. Y., Fung, J., Ma, H. T., Lei, M. W., Seto, W. K., & Yuen, M. F. (2023). Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac383
Vancouver
Chow N, Wong D, Lai CL, Mak LY, Fung J, Ma HT, et al. Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac383
BibTeX
@article{Chow2023,
author = {Chow, Ning and Wong, Danny and Lai, Ching-Lung and Mak, Lung-Yi and Fung, James and Ma, Hoi-Tang and Lei, Meng-Wai and Seto, Wai-Kay and Yuen, Man-Fung},
title = {Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac383}
}
EUVIMED